452 related articles for article (PubMed ID: 21847518)
1. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
Yoshida K; Okimoto N; Kishimoto M; Fukano H; Hara H; Yoneyama H; Moriya O; Kawanishi M; Kimura M; Matsushima T; Niki Y
J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis.
Pea F; Pavan F; Lugatti E; Dolcet F; Talmassons G; Screm MC; Furlanut M
Clin Pharmacokinet; 2006; 45(3):287-95. PubMed ID: 16509760
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
Patel T; Pearl J; Williams J; Haverstock D; Church D
Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
[TBL] [Abstract][Full Text] [Related]
4. Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.
Öbrink-Hansen K; Hardlei TF; Brock B; Jensen-Fangel S; Kragh Thomsen M; Petersen E; Kreilgaard M
Antimicrob Agents Chemother; 2015 Apr; 59(4):2398-404. PubMed ID: 25666151
[TBL] [Abstract][Full Text] [Related]
5. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
Stass H; Dalhoff A
Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
Noreddin AM; Reese AA; Ostroski M; Hoban DJ; Zhanel GG
Clin Ther; 2007 Dec; 29(12):2685-9. PubMed ID: 18201584
[TBL] [Abstract][Full Text] [Related]
7. [A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial].
Jardim JR; Rico G; de la Roza C; Obispo E; Urueta J; Wolff M; Miravitlles M;
Arch Bronconeumol; 2003 Sep; 39(9):387-93. PubMed ID: 12975069
[TBL] [Abstract][Full Text] [Related]
8. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
Wispelwey B; Schafer KR
Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
[TBL] [Abstract][Full Text] [Related]
9. Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
Lee SY; Fan HW; Sutherland C; DeRyke AC; Nicolau DP
Drugs R D; 2007; 8(2):69-77. PubMed ID: 17324004
[TBL] [Abstract][Full Text] [Related]
10. Proposed Pharmacokinetic-Pharmacodynamic Breakpoint of Garenoxacin and Other Quinolones.
Yamagishi Y; Shibata T; Nakagawa S; Nomura N; Mitsuyama J; Mikamo H
Jpn J Infect Dis; 2017 Nov; 70(6):616-620. PubMed ID: 28890509
[TBL] [Abstract][Full Text] [Related]
11. Moxifloxacin in respiratory tract infections.
Miravitlles M
Expert Opin Pharmacother; 2005 Feb; 6(2):283-93. PubMed ID: 15757424
[TBL] [Abstract][Full Text] [Related]
12. Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin.
MacGowan A; Rogers C; Holt HA; Wootton M; Bowker K
J Antimicrob Chemother; 2000 Jul; 46(1):73-8. PubMed ID: 10882692
[TBL] [Abstract][Full Text] [Related]
13. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
[TBL] [Abstract][Full Text] [Related]
14. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
Nightingale CH
Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of garenoxacin tablets on bacterial pneumonia: postmarketing surveillance in Japan.
Izumikawa K; Watanabe A; Miyashita N; Ishida T; Hosono H; Kushimoto S; Kohno S
J Infect Chemother; 2014 Sep; 20(9):549-57. PubMed ID: 24934887
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.
Noel AR; Bowker KE; Macgowan AP
Antimicrob Agents Chemother; 2005 Oct; 49(10):4234-9. PubMed ID: 16189103
[TBL] [Abstract][Full Text] [Related]
17. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
[TBL] [Abstract][Full Text] [Related]
19. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
MacGowan AP; Rogers CA; Holt HA; Bowker KE
Antimicrob Agents Chemother; 2003 Mar; 47(3):1088-95. PubMed ID: 12604546
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
Zervos M; Martinez FJ; Amsden GW; Rothermel CD; Treadway G
Int J Antimicrob Agents; 2007 Jan; 29(1):56-61. PubMed ID: 17189096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
